PCVX Share Price Performance
US$58.13
26.38 (83.09%)
46.7% undervalued intrinsic discount
US$109.00
Fair Value
Price US$58.13
AnalystConsensusTarget US$109.00
AnalystHighTarget US$163.00
AnalystLowTarget US$67.00
Fair ValueUS$109.00
Share Pricen/a
Vaxcyte, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 16 Fair Values set on narratives written by author
PCVX Community Narratives
AN
Fair Value
·Fair Value US$109 46.7% undervalued intrinsic discount
Future Late Stage Vaccine Programs And Manufacturing Capacity Will Drive Long Term Opportunity
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value US$163 64.3% undervalued intrinsic discount
Late Stage Vaccine Programs And New Manufacturing Capacity Will Underpin Long Term Upside
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$67 13.2% undervalued intrinsic discount
Late Stage Vaccine Trials And Manufacturing Buildout Will Shape Balanced Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Vaxcyte
46.7% undervalued intrinsic discount
Future Late Stage Vaccine Programs And Manufacturing Capacity Will Drive Long Term Opportunity
View narrativeAN
Published 19 Mar
Vaxcyte
64.3% undervalued intrinsic discount
Late Stage Vaccine Programs And New Manufacturing Capacity Will Underpin Long Term Upside
View narrativeAN
Published 5 Mar
Vaxcyte
13.2% undervalued intrinsic discount
Late Stage Vaccine Trials And Manufacturing Buildout Will Shape Balanced Long Term Outlook
View narrativeAN
Published 3 Mar
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Future Late Stage Vaccine Programs And Manufacturing Capacity Will Drive Long Term Opportunity
Fair Value: US$109 46.7% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Late Stage Vaccine Programs And New Manufacturing Capacity Will Underpin Long Term Upside
Fair Value: US$163 64.3% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Late Stage Vaccine Trials And Manufacturing Buildout Will Shape Balanced Long Term Outlook
Fair Value: US$67 13.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Vaxcyte, Inc. Key Details
About PCVX
- Founded
- 2013
- Employees
- 507
- CEO
- WebsiteView website
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
